Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT06181006
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT06180980
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of LY3410738 in Healthy Adult Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT06181045
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06180967
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT06181084
- Locations
- 🇺🇸
Labcorp Clinical Research, Daytona Beach, Florida, United States
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 9
- Registration Number
- NCT06180954
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT06176768
- Locations
- 🇺🇸
Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
🇺🇸Driven Research, Coral Gables, Florida, United States
A Relative Bioavailability Study of LY3454738 in Healthy Participants
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT06173895
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT06169982
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06165146
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States